High Tumor Mutation Burden Fails to Predict Immune Checkpoint Blockade Response Across All Cancer Types

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2021 Mar 19

PMID 33736924

Citations 484

Authors

D J McGrail

P G Pilie

N U Rashid

L Voorwerk

M Slagter

M Kok

E Jonasch

M Khasraw

A B Heimberger

B Lim

N T Ueno

J K Litton

R Ferrarotto

J T Chang

S L Moulder

S-Y Lin

Affiliations

Soon will be listed here.

Abstract

Background: High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer approval of ICB treatment for any TMB-H tumor, as assessed by the targeted FoundationOne CDx assay in nine tumor types, the utility of this biomarker has not been fully demonstrated across all cancers.

Patients And Methods: Data from over 10 000 patient tumors included in The Cancer Genome Atlas were used to compare approaches to determine TMB and identify the correlation between predicted neoantigen load and CD8 T cells. Association of TMB with ICB treatment outcomes was analyzed by both objective response rates (ORRs, N = 1551) and overall survival (OS, N = 1936).

Results: In cancer types where CD8 T-cell levels positively correlated with neoantigen load, such as melanoma, lung, and bladder cancers, TMB-H tumors exhibited a 39.8% ORR to ICB [95% confidence interval (CI) 34.9-44.8], which was significantly higher than that observed in low TMB (TMB-L) tumors [odds ratio (OR) = 4.1, 95% CI 2.9-5.8, P < 2 × 10]. In cancer types that showed no relationship between CD8 T-cell levels and neoantigen load, such as breast cancer, prostate cancer, and glioma, TMB-H tumors failed to achieve a 20% ORR (ORR = 15.3%, 95% CI 9.2-23.4, P = 0.95), and exhibited a significantly lower ORR relative to TMB-L tumors (OR = 0.46, 95% CI 0.24-0.88, P = 0.02). Bulk ORRs were not significantly different between the two categories of tumors (P = 0.10) for patient cohorts assessed. Equivalent results were obtained by analyzing OS and by treating TMB as a continuous variable.

Conclusions: Our analysis failed to support application of TMB-H as a biomarker for treatment with ICB in all solid cancer types. Further tumor type-specific studies are warranted.

Citing Articles

Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.

Kuras M, Betancourt L, Hong R, Szadai L, Rodriguez J, Horvatovich P Cancers (Basel). 2025; 17(5).

PMID: 40075679 PMC: 11899103. DOI: 10.3390/cancers17050832.

Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer.

Eklund E, Svensson J, Naslund L, Yhr M, Sayin S, Wiel C J Exp Clin Cancer Res. 2025; 44(1):75.

PMID: 40011914 PMC: 11866712. DOI: 10.1186/s13046-025-03342-6.

Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes.

Shi R, Sun J, Zhou Z, Shi M, Wang X, Gao Z NPJ Precis Oncol. 2025; 9(1):54.

PMID: 40011681 PMC: 11865301. DOI: 10.1038/s41698-025-00842-8.

Exploration of the clonal evolution and construction of the tumor clonal evolution rate as a prognostic indicator in metastatic breast cancer.

Lv D, Lan B, Guo Q, Yi Z, Qian H, Guan Y BMC Med. 2025; 23(1):122.

PMID: 40001125 PMC: 11863457. DOI: 10.1186/s12916-025-03959-6.

Clinical metric of tumor mutational burden depicts colorectal cancer patients at the extremes.

Zheng M Clin Transl Oncol. 2025; .

PMID: 39984774 DOI: 10.1007/s12094-025-03873-6.

References

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

Gubin M, Artyomov M, Mardis E, Schreiber R . Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015; 125(9):3413-21. PMC: 4588307. DOI: 10.1172/JCI80008. View

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Chalabi M, Fanchi L, Dijkstra K, van den Berg J, Aalbers A, Sikorska K . Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020; 26(4):566-576. DOI: 10.1038/s41591-020-0805-8. View

Subudhi S, Vence L, Zhao H, Blando J, Yadav S, Xiong Q . Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020; 12(537). DOI: 10.1126/scitranslmed.aaz3577. View

Goodman A, Kato S, Bazhenova L, Patel S, Frampton G, Miller V . Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017; 16(11):2598-2608. PMC: 5670009. DOI: 10.1158/1535-7163.MCT-17-0386. View

Gromeier M, Brown M, Zhang G, Lin X, Chen Y, Wei Z . Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun. 2021; 12(1):352. PMC: 7806846. DOI: 10.1038/s41467-020-20469-6. View

10.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

11.

Kazdal D, Endris V, Allgauer M, Kriegsmann M, Leichsenring J, Volckmar A . Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. J Thorac Oncol. 2019; 14(11):1935-1947. DOI: 10.1016/j.jtho.2019.07.006. View

12.

Khasraw M, Walsh K, Heimberger A, Ashley D . What is the Burden of Proof for Tumor Mutational Burden in gliomas?. Neuro Oncol. 2020; . PMC: 7849945. DOI: 10.1093/neuonc/noaa256. View

13.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

14.

McGrail D, Federico L, Li Y, Dai H, Lu Y, Mills G . Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun. 2018; 9(1):1317. PMC: 5882811. DOI: 10.1038/s41467-018-03730-x. View

15.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

16.

Subbiah V, Solit D, Chan T, Kurzrock R . The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Ann Oncol. 2020; 31(9):1115-1118. DOI: 10.1016/j.annonc.2020.07.002. View

17.

Chen X, Chang J . Planning bioinformatics workflows using an expert system. Bioinformatics. 2017; 33(8):1210-1215. PMC: 5860174. DOI: 10.1093/bioinformatics/btw817. View

18.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

19.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

20.

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L . Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019; 25(12):1916-1927. PMC: 6898788. DOI: 10.1038/s41591-019-0654-5. View